Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the value of induction Erlotinib therapy before
thoracotomy or radiotherapy in ⅢA-N2 (confirmed by mediastinoscopy or PET) non-small cell
lung cancer (NSCLC) selected by epidermal growth factor receptor (EGFR) gene analysis and
initial to explore a new treatment strategy for ⅢA-N2 NSCLC.